Guidelines for New Investigator Award


Description

Eligibility

Conditions of Support

Tenure

Stipend

Paying of Stipend
Equipment Purchases

Preparing Electronic Files

Application


Description

The KRESCENT program New Investigator Award is awarded to individuals who have clearly demonstrated excellence during their pre-doctoral and post-doctoral training in kidney disease. The Award provides salary support for up to three years of the faculty appointment at the rank of Assistant Professor or its equivalent at a Canadian University.

The purpose of this award is to assist such an individual to become established as a fully independent investigator in the field of kidney disease.

Preference may be given to candidates who have been awarded and successfully completed a KRESCENT program Post Doctoral Fellowship or Allied Health Doctoral Scholarship.

Application for this award must be initiated by the university or the institution at which the candidate will conduct the proposed research. The university or institution is expected to guarantee the applicant appropriate academic rank and to provide adequate space and facilities for the investigator’s research, commensurate with the status of the individual in terms of experience and level of support by the Program.

An awardee may not be in receipt of another major personnel support award (i.e. from international, national or provincial funding agencies) at the same time as holding the New Investigator Award from the KRESCENT program.

The quality of the proposed research plan is an important component in the evaluation of the application.  Therefore, a clear, concise and comprehensive description of the proposed research plan must be given.  In addition, the role of the New Investigator in the proposed research must be clearly defined including how the execution of the research plan will contribute to the candidate’s development as an independent researcher.

The awardee must show proof of application for a grant-in-aid (or research grant) in support of the proposed research plan at the time of this award. Such grants must be administered by peer review granting agencies, approved by the KRESCENT program, for example The Kidney Foundation of Canada. (See Eligibility section for specific requirements).


Eligibility

At the time of commencement of the New Investigator Award no more than three years may have passed since the date of the first faculty appointment.

Candidates must hold an appointment at a Canadian university at Assistant Professor level or equivalent.

Candidates must have a MD, PhD or equivalent degree.

Applications in clinical research will be considered only if it is clear from the application that at least 80% of the applicant’s time and effort will be devoted to the research project(s).

The New Investigator Faculty Award is contingent on the following additional requirements with regard to grant-in-aid support for the proposed research.

-
During year one and two of this award the awardee must show proof of submission of grant-in-aid applications to granting agencies that conduct peer reviews of the proposed research plan.
 - For the third year of the award the awardee must hold a grant-in-aid as a Principal Investigator for the proposed research plan from an agency that uses peer review process recognized by the KRESCENT program.


Conditions of Support

The awardee must participate and successfully complete the KRESCENT Core Curriculum (for details see KRESCENT Curriculum document). Failure to participate in and successfully complete the required elements of Core Curriculum will lead to withdrawal of ongoing funding support from the KRESCENT program


Tenure

The New Investigator Award is tenable at a university or affiliated institution in Canada.

The award will normally commence on July 1 and will run for the eligible duration.

The awardee must devote no less than 80% of his/her time to the proposed research.  The remainder of the New Investigator’s time may be devoted to teaching, administration, clinical activity or activity related to the research project.  The KRESCENT program imposes no restriction on the additional income the New Investigator may earn provided it is within the guidelines of the sponsoring university or institution and that such activity does not impinge upon the time dedicated to the proposed research.

An award may be terminated at any time for good cause by the awardee, the sponsoring institution or the KRESCENT program.


Stipend

The amount of the award is determined by the following salary scales (amounts in Canadian dollars):

The stipend for those holding a MD or equivalent degree is $70,000 per year.

The stipend for those holding a PhD without a MD or equivalent degree is $60,000 per year.

The KRESCENT program also offers to match up to a maximum of $25,000 of Infrastructure Support (laboratory start-up costs and support staff) awarded during the period of the New Investigator Award from the sponsoring university or institution. The Candidate must apply for the Infrastructure Support at the same time as for this award but a separate budget should be provided. The Candidate also must submit proof of matching institutional support. It is the intention of the KRESCENT program that the Infrastructure Support be used to the direct benefit/assistance of the awardee’s research plan.

Some examples of appropriate uses of this infrastructure support would be the purchase of software, equipment, other technology or stipends for graduate students and summer students; examples of inappropriate uses of these funds would be for supplementation of the awardee’s salary or for general institutional overhead.


Payment of Stipend

Awards will be paid to the institution, where the award is held, in quarterly installments.

The Infrastructure Support will be paid in two half-yearly installments during the first year of this award.


Equipment Purchases

Title to equipment purchased with the Infrastructure Support funds rests with the Granting Program. During tenure or upon termination of the award, such equipment will, unless otherwise stipulated by the KRESCENT program, be vested in the institution where the awardee carried out the research.

 

Preparing Electronic Files

Electronic files must be submitted on a CD; DVDs are not accepted. When naming your files, add numbers to your file names, in ascending order, so that the documents appear in correct order on the CD.

Name electronic files for New Investigator Awards as follows:

00-DOE-J 2010 KNIA Application.pdf
00-DOE-J 2010 KNIA Application.doc (please include original application in MS Word format)
01-DOE-J 2010 KNIA Letter 1.pdf (institution’s acceptance letter)
01-DOE-J 2010 KNIA Letter 2.pdf (proof of institution’s infrastructure support)
02-DOE-J 2010 KNIA CV Applicant.pdf
03-DOE-J 2010 KNIA Publication 1.pdf
03-DOE-J 2010 KNIA Publication 2.pdf
03-DOE-J 2010 KNIA Publication 3.pdf
03-DOE-J 2010 KNIA Publication 4.pdf
03-DOE-J 2010 KNIA Publication 5.pdf
04-DOE-J 2010 KNIA Infrastructure Support 1.pdf (supporting documents)
04-DOE-J 2010 KNIA Infrastructure Support 2.pdf

 

Application

Applications must be submitted on the prescribed forms, which are available on the KRESCENT program Website or at the National Office of The Kidney Foundation of Canada.

The original application and one (1) PDF copy on CD, along with all addenda (see Application Checklist for details) must be forward to:

KRESCENT Program
Nancy Lamothe
Coordinator, KRESCENT Program
National Office
The Kidney Foundation of Canada
300-5165 Sherbrooke Street, West
Montreal, Quebec H4A 1T6


Applications and all addenda must be courier marked January 15, 2010. Applications courier marked later than January 15, 2010 will not be reviewed.

Important: The KRESCENT program has implemented a zero-tolerance policy for late and incomplete applications. Failure to adhere to the guidelines and regulations will result in rejection of an application, without possibility of appeal.

The KRESCENT Program is a Strategic Training Program developed and supported by:

                                                    


With additional generous support from:

AMGEN               Baxter Corporation               Merck-Frosst Canada Ltd.             Ortho Biotech              RocheShire BioChem Inc.

© 2005 The Kidney Foundation of Canada